Live feed07:30:00·956dPRReleasevia QuantisnowInitial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class ProfileByQuantisnow·Wall Street's wire, on your screen.ORIC· Oric Pharmaceuticals Inc.Health Care
